Schering Corporation

Merck Sharp + Dohme Corp.

Lisa S Silverman

Deen Tulshian

Julius J Matasi

Bernard R Neustadt

Ginny Dai Ho

Francis M Cuss

John A Hey

Richard W Chapman

Ana Bercovici

Robbie L McLeod

William J Greenlee

Samuel Chackalamannil

Duane A Burnett

Wen-Lian Wu

Yan Xia

Craig D Boyle

Neil A Lindo

Thavalakulamgara K Sasikumar

Martin Domalski

Li Qiang

Peter Korakas

John P Caldwell

Eugenia Y Kiselgof

Martin S Domalski

Sasikumar K Thavalakulamgara

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein

Adenosine Areceptor antagonists

In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J-J, X, and R-Rare as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease. 

mGluR1 antagonists as therapeutic agents

In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J-J, X, and R&#x2014;Rare as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease. 

Novel compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein:

High affinity ligands for nociceptin receptor ORL-1

Disclosed are compounds having the structural formulaor pharmaceutically acceptable salts or solvates thereof, wherein

Adenosine A2a receptor antagonists

Compounds having the structural formula Ior a pharmaceutically acceptable salt thereof, wherein

Growing community of inventors

Metuchen, NJ, United States of America

Lisa S Silverman